Reference is made to the notice published on 11 November 2020 that called for a general meeting in Eqology AS ("Eqology") to resolve a de-listing of Eqology's shares from NOTC during December 2020. ImmunoPharma AS (ImmunoPharma), which controls more than 2/3 of the outstanding shares in Eqology, requested a de-listing of Eqology's shares. Due to feedback from certain minority shareholders, ImmunoPharma has requested the board of Eqology to cancel the extraordinary general meeting called for at Friday 20 November at 1 pm CET. Consequently, and in light of ImmunoPharma's shareholding, the board of Eqology has today decided that said extraordinary general meeting is cancelled. 

ImmunoPharma has further informed the board of Eqology that the contemplated offer for Eqology shares set forth in the notice on 6 November 2020 is withdrawn, and that ImmunoPharma will consider to offer to buy outstanding shares in Eqology following Eqology's adoption of the annual accounts for 2020.

For questions regarding the cancellation of the general meeting, contact:

Roar Arnstad
CEO
E-mail: roar.arnstad@eqology.no

Christian Espeseth
Chairman of the board "